98%
921
2 minutes
20
Antipsychotic drugs (APDs) represent a cornerstone in the treatment of schizophrenia and other psychoses. The effectiveness of the first generation (typical) APDs are hampered by so-called extrapyramidal side effects, and they have gradually been replaced by second (atypical) and third-generation APDs, with less extrapyramidal side effects and, in some cases, improved efficacy. However, the use of many of the current APDs has been limited due to their propensity to stimulate appetite, weight gain, and increased risk for developing type 2 diabetes and cardiovascular disease in this patient group. The mechanisms behind the appetite-stimulating effects of the various APDs are not fully elucidated, partly because their diverse receptor binding profiles may affect different downstream pathways. It is critical to identify the molecular mechanisms underlying drug-induced hyperphagia, both because this may lead to the development of new APDs, with lower appetite-stimulating effects but also because such insight may provide new knowledge about appetite regulation in general. Hence, in this review, we discuss the receptor binding profile of various APDs in relation to the potential mechanisms by which they affect appetite.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762106 | PMC |
http://dx.doi.org/10.3389/fnut.2021.815456 | DOI Listing |
BJPsych Open
September 2025
Faculty of Pharmacy, Université Laval, Quebec, Canada.
Background: The decision-making process regarding antipsychotic continuation or discontinuation following remission from first-episode psychosis (FEP) remains complex and underresearched. While discontinuation increases the risk of relapse, concerns over long-term side-effects such as metabolic disturbances and extrapyramidal symptoms also exist. Current guidelines recommend maintaining antipsychotics for 1-5 years, emphasising shared decision-making (SDM) between clinicians and patients.
View Article and Find Full Text PDFAm J Psychiatry
September 2025
Mind, Brain Imaging, and Neuroethics Research Unit, The Royal's Institute of Mental Health Research, University of Ottawa, Ottawa.
BMC Psychiatry
August 2025
Department of psychiatry, College Health Science, Mekelle University, Mekelle, Ethiopia.
Background: Schizophrenia is one of the most disruptive of neuropsychiatric disorders, affecting around 1% of the world's population. Antipsychotic medications have been the backbone of schizophrenia treatment for the past 50 years. Extrapyramidal side effects of antipsychotic medication are a major problem which is associated with various factors.
View Article and Find Full Text PDFSensors (Basel)
August 2025
School of Electrical and Data Engineering, University of Technology Sydney, 15 Broadway, Ultimo, Sydney, NSW 2007, Australia.
Extrapyramidal symptoms encompass features of Parkinsonism, including bradykinesia, cogwheel rigidity, and resting tremors, which contribute to motor impairments hindering handwriting and speech. In this study, we analyzed voice data captured using a voice sensor setup from 94 patients exhibiting varying levels of EPS and 30 unaffected controls. Each participant provided 13 recordings of repeated vowel and consonant sounds.
View Article and Find Full Text PDFDiseases
August 2025
Inpatient Psychiatric Facility Service, College Medical Center, Long Beach, CA 90806, USA.
Aripiprazole is a third-generation antipsychotic, approved in 2002, notable for its partial agonism of the Dopamine D2 receptor and lower risk of metabolic and extrapyramidal adverse effects. It is available in a long-acting injectable formulation, which is very useful for maintaining medication compliance, which is crucial for preventing recurrent psychotic episodes in patients. Additionally, the aripiprazole long-acting injectable is frequently combined with other antipsychotic medications in acute settings to manage refractory symptoms.
View Article and Find Full Text PDF